Canada markets closed

Aclarion, Inc. (ACON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9200-0.0093 (-1.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.9293
Open0.9200
Bid0.8901 x 1000
Ask0.9900 x 800
Day's Range0.8600 - 0.9298
52 Week Range0.7830 - 4.0500
Volume40,328
Avg. Volume1,329,532
Market Cap7.196M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

    Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two YearsTwo Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022SAN MATEO, CA / ACCESSWIRE / June 22, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that the Company will

  • ACCESSWIRE

    Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering

    SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 share

  • ACCESSWIRE

    Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering

    SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock.